Metsera strengthens case for Pfizer buyout with latest study data

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.

By Jonathan Gardner • Sept. 30, 2025

Moonlake shares crash on mixed study results for immune drug

Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and “undifferentiated,” erasing more than four-fifths of the company’s market value.

By Ben Fidler • Sept. 29, 2025

Explore the Trendline➔

Oncology's research boom

More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

By BioPharma Dive staff

Lilly stops trial of muscle-sparing obesity drug

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines. 

By Jonathan Gardner • Sept. 25, 2025

Cancer patients are living longer than ever. Pain drugmakers haven’t kept up.

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily pain. Doctors fear that’s bound to continue.

By Jacob Bell • Sept. 25, 2025

UniQure to seek approval of Huntington’s gene therapy after trial win

New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have “massive effects on patients’ lives,” an investigator said.

By Jonathan Gardner • Sept. 24, 2025

Acadia to scrap Prader-Willi drug after study setback

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential competitor to Soleno’s fast-selling Vykat. 

By Kristin Jensen • Sept. 24, 2025

Bristol Myers says next-gen blood cancer drug hits goal in key study

The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.

By Jonathan Gardner • Sept. 23, 2025

Meet the new EmVenio – where science meets people

EmVenio makes clinical trial participation easier, more inclusive and more reflective of our world.

By EmVenio Clinical Research • Sept. 22, 2025

Roivant pill succeeds in rare inflammatory disease trial

A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis symptoms and steroid use.

By Jonathan Gardner • Sept. 17, 2025

ATyr shares plunge on trial miss in inflammatory lung disease

The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its main study goal.

By Jonathan Gardner • Sept. 15, 2025

Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology

Early academic research suggests various ways weight loss drugs could have an impact in cancer care.

By Michael Gibney • Sept. 12, 2025

BioNTech says dual-acting lung cancer drug helped shrink tumors

The Bristol Myers-partnered bispecific antibody kept small cell lung cancer under control in participants enrolled in a Phase 2 trial.

By Jonathan Gardner • Sept. 8, 2025

A new class of sleep drugs draws Wall Street’s attention

Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.

By Jacob Bell • Sept. 8, 2025

Pfizer, BioNTech showcase new data supporting COVID booster

The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, answering calls for more corroborating evidence.

By Delilah Alvarado • Sept. 8, 2025

New Summit data clouds approval pathway in lung cancer

A combination of ivonescimab and chemo didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.

By Jonathan Gardner • Sept. 8, 2025

Rapport shares double on better-than-expected seizure drug data

One analysts called the Phase 2 study results a “best-case scenario” for a drug Rapport is developing to treat focal onset seizures.

By Ned Pagliarulo • Sept. 8, 2025

How sponsors are staying ahead in the obesity trial landscape

Aligning digital innovation with thoughtful design is accelerating progress.

Sept. 8, 2025

Harnessing the power of AI to detect ATTR-CM

From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.

Sept. 8, 2025

Sanofi’s touted eczema drug hits study goal, but data fall short of expectations

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug class once viewed as particularly promising.

By Kristin Jensen • Sept. 4, 2025

Wave shares sink on new study results for RNA editing drug

Updated findings from Wave’s pioneering trial continued to show its RNA editing therapy is working as intended, but wasn’t as effective in testing as investors had hoped.  

By Ben Fidler • Sept. 3, 2025

Ionis looks to expand use of lipid-lowering drug after trial hits goal

Tryngolza, the first wholly owned drug Ionis has launched, helped people with high triglyceride levels that aren’t genetically driven.

By Jonathan Gardner • Sept. 2, 2025

Lilly says breast cancer drug extended survival in study

Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy.

By Delilah Alvarado • Aug. 27, 2025

Lilly to submit obesity pill after hitting goal in third late-stage trial

In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.

By Jonathan Gardner • Aug. 26, 2025

RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial

Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn't appear as effective.

By Ned Pagliarulo • Updated Aug. 26, 2025

Viking shares sink as obesity pill misses expectations in key study

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations among people receiving Viking’s drug. 

By Jonathan Gardner • Aug. 19, 2025